Bachem Holding AG
SIX:BANB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
55.15
91.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Bachem Holding AG
Bachem Holding AG
Net Income (Common)
Bachem Holding AG
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bachem Holding AG
SIX:BANB
|
Net Income (Common)
CHf113.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Net Income (Common)
CHf128.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Net Income (Common)
CHf573m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
|
Tecan Group AG
SIX:TECN
|
Net Income (Common)
CHf101.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Net Income (Common)
-€51.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Net Income (Common)
CHf26.3m
|
CAGR 3-Years
80%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
Bachem Holding AG
Glance View
In the heart of the Swiss pharmaceutical industry, Bachem Holding AG has carved out a distinct niche as a leading player in the peptide manufacturing landscape. Founded by Peter Grogg in 1971, Bachem has grown from a modest laboratory venture into a global powerhouse with an exceptional focus on peptides and oligonucleotide development. These biomolecules, small chains of amino acids, and nucleotides respectively, play crucial roles in modern therapeutics, acting as key components in drug design for treating various ailments. From its headquarters in Bubendorf, Switzerland, Bachem leverages cutting-edge technologies to enhance the purity and scalability of peptide production, meeting the demand from pharmaceutical and biotechnology companies worldwide. By establishing a robust supply chain and maintaining high standards of quality control, the company ensures the reliability and success of its partnerships. At the core of Bachem's business model is the offering of customized products and services tailored to client-specific needs, ranging from research-grade to commercial-scale production. The company generates revenue through long-term contracts and ongoing relationships with key players in the global pharmaceutical industry. As drug discovery advances, Bachem’s role in providing essential active pharmaceutical ingredients (APIs) becomes increasingly central, facilitating the development of novel therapies. The company also invests heavily in research and development to continuously refine its manufacturing processes and expand its service portfolio. By marrying scientific expertise with strategic foresight, Bachem not only anchors itself in the present pharmaceutical landscape but also positions itself for future growth in the biotechnology sector.
See Also
What is Bachem Holding AG's Net Income (Common)?
Net Income (Common)
113.6m
CHF
Based on the financial report for Jun 30, 2024, Bachem Holding AG's Net Income (Common) amounts to 113.6m CHF.
What is Bachem Holding AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%
Over the last year, the Net Income (Common) growth was 15%. The average annual Net Income (Common) growth rates for Bachem Holding AG have been 5% over the past three years , 18% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
